Details for New Drug Application (NDA): 214799

NDA 214799 describes METOLAZONE, which is a drug marketed by Alembic, Ani Pharms, Bayshore Pharms Llc, Chemistry Hlth, Innogenix, Mylan, Ne Rx Pharma, Renata, Roxane, Rubicon, Sandoz, and Watson Labs, and is included in thirteen NDAs. It is available from eighteen suppliers. Additional details are available on the METOLAZONE profile page.

The generic ingredient in METOLAZONE is metolazone. There are ten drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the metolazone profile page.

Summary for 214799

Tradename:	METOLAZONE
Applicant:	Bayshore Pharms Llc
Ingredient:	metolazone
Patents:	0

Pharmacology for NDA: 214799

Physiological Effect

Increased Diuresis

Medical Subject Heading (MeSH) Categories for 214799

Antihypertensive Agents

Diuretics

Sodium Chloride Symporter Inhibitors

Suppliers and Packaging for NDA: 214799

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
METOLAZONE	metolazone	TABLET;ORAL	214799	ANDA	Bayshore Pharmaceuticals LLC	76385-136	76385-136-01	100 TABLET in 1 BOTTLE (76385-136-01)
METOLAZONE	metolazone	TABLET;ORAL	214799	ANDA	Bayshore Pharmaceuticals LLC	76385-137	76385-137-01	100 TABLET in 1 BOTTLE (76385-137-01)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	2.5MG
Approval Date:	Mar 30, 2021	TE:	AB	RLD:	No

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	5MG
Approval Date:	Mar 30, 2021	TE:	AB	RLD:	No

Profile for product number 003

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	10MG
Approval Date:	Mar 30, 2021	TE:	AB	RLD:	No

Complete Access Available with Subscription